Tenet Healthcare Corporation logo

Tenet Healthcare Corporation(THC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
4-STAR RATING
STRONG BUY
BUY for 22 days
PROFIT SINCE LAST BUY
+3.96% ▲
LAST CLOSE
$286.03
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for THC

11/13/2026: THC (4-star) is a STRONG-BUY. BUY for 22 days. Simulated Profits (3.96%). Updated daily EoD!

Tenet Healthcare Corporation is a major U.S. operator of hospitals and outpatient surgical centers, increasingly known for its high-margin ambulatory surgery platform, USPI. The company's primary strength lies in its strategic shift toward outpatient surgical care, which is less capital-intensive and generally more profitable than traditional inpatient hospital services. The investment story centers on this transition, though investors must monitor risks related to significant corporate debt, labor market pressures, and potential changes in government reimbursement policies. Tenet may suit growth-oriented investors looking for exposure to the shift toward outpatient medical care, provided they are comfortable with the inherent regulatory and execution risks in the healthcare sector.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company’s focus on the fast-growing ambulatory surgical services market provides a compelling growth narrative.
Momentum investorStrong fit while signal remains positiveStrong operational performance and margin expansion have historically driven positive price momentum.
Value investorMixed fitValuation is often tied to market perceptions of healthcare policy risks and debt levels, making it a complex value play.
Dividend investorWeak fitThe company does not pay a cash dividend, focusing capital on growth and debt repayment instead.
Low-risk investorWeak fitHigh leverage and regulatory exposure create volatility that may not suit conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock is sensitive to changes in healthcare policy and broader market sentiment regarding medical services.
Valuation riskMediumMarket valuations can fluctuate based on perceived shifts in the regulatory environment for hospital providers.
Competition risk (Hospital and ASC operators)MediumTenet faces constant competitive pressure from both large hospital systems and specialized outpatient providers.
Business qualityMediumWhile the ambulatory business is high-quality, the legacy hospital business carries higher operational risks.
Dividend incomeLow / noneThe absence of a dividend removes this stock as a candidate for income-focused portfolios.
Execution riskMediumSuccessfully managing the shift in patient care settings and reducing debt requires consistent operational excellence.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 22.76B USD
Price to earnings Ratio 8.34
1Y Target Price 307.32
Price to earnings Ratio 8.34
1Y Target Price 307.32
Volume (30-day avg) 800.3K shares
Beta 1.2
52 Weeks Range 157.58 - 301.44
Updated Date 11/13/2026
52 Weeks Range 157.58 - 301.44
Updated Date 11/13/2026
Dividends yield (FY) -
Basic EPS (TTM) 34.29

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 80.46%
Avg. Invested days 44
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
THC receives a 4-star rating, supported by solid unit economics, solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
THC has solid overall fundamentals (4 stars), with solid financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 11.9%) is partially offset by negative earnings growth (-56.0%), moderate revenue growth (+3.1%), soft profitability (net margin 6.6%).

Financial Health Rating

★★★★★
THC's financial health is supported by strong cash strength, including free-cash-flow generation of $2.5B (11.9% of revenue). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is THC's strongest growth driver at +126.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+3.1%, moderate) and earnings growth (-56.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 100.4% and approximately 99.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.98%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 10.99%
T. Rowe Price Associates, Inc. 10.00%
Boston Partners Global Investors, Inc 5.57%
Vanguard Portfolio Management, LLC 5.33%
FMR Inc 5.02%

Unit Economics (Per $1K Revenue)

★★★★★
THC generates approximately $823 of gross profit, $161 of operating income, and $119 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and solid cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 15.46%

Quantitative Style Profile

★★★★★
THC has a high-quality, large-cap, liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedQuality TiltHigh VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Ambulatory Care (USPI)Outpatient surgical centers, surgical hospitals, and imaging centers.This is the growth engine of the company, focusing on efficient, elective, and outpatient surgical procedures.
Hospital OperationsAcute care hospitals, emergency rooms, and inpatient specialized services.This provides the core service volume but is more capital-intensive and subject to higher labor cost fluctuations.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When Before Market
Estimate 4.6
Actual 6.64

Profitability

Profit Margin 13.09%
Operating Margin (TTM) 19.12%

Management Effectiveness

Return on Assets (TTM) 8.68%
Return on Equity (TTM) 41.7%

Valuation

Trailing PE 8.34
Forward PE 15.08
Enterprise Value 33.40B
Price to Sales(TTM) 1.03
Enterprise Value 33.40B
Price to Sales(TTM) 1.03
Enterprise Value to Revenue 1.41
Enterprise Value to EBITDA 5.19
Shares Outstanding 79.59M
Shares Floating 78.75M
Shares Outstanding 79.59M
Shares Floating 78.75M
Percent Insiders 0.98
Percent Institutions 100.43

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.